The 2006 silicone breast implant approval was a major U.S. regulatory milestone, but it was not a declaration that silicone implants were risk-free or guaranteed to last for life. In November 2006, the U.S. Food and Drug Administration approved two silicone gel-filled breast implant applications: Mentor MemoryGel and Inamed’s silicone-filled implant, later associated with the Natrelle line. The approvals allowed defined uses under approved labelling, including breast augmentation for women aged 22 or older and breast reconstruction for women of any age.
The earlier 2000 saline approvals were also specific regulatory decisions, not a general certificate for every saline device ever made. On 10 May 2000, the FDA approved Mentor’s Saline-Filled and Spectrum Mammary Prostheses and McGhan’s saline-filled breast implant under PMA numbers P990075 and P990074. These milestones made saline-filled implants available for labelled augmentation and reconstruction indications, while the FDA continued to require evidence, labelling and post-approval oversight.
This article asks a narrower question than “are breast implants safe?” It explains what the 2000 and 2006 decisions established, why approval conditions included continuing studies, what those studies added to the evidence base and why incomplete follow-up limits certainty. The history concerns U.S. Food and Drug Administration decisions and U.S. evidence programmes. It is not a recommendation for a specific filler, brand, surface or operation, and historical results should not be treated as an individual prediction.
What the two approval milestones actually were
The 2000 saline approvals
The FDA’s PMA database records 10 May 2000 as the decision date for both Mentor’s P990075 application and McGhan’s P990074 application. The records identify the devices as inflatable internal saline breast prostheses. The approval orders were for particular products and applicants, rather than for “saline implants” as one undifferentiated category.
The FDA’s current overview explains that saline-filled breast implants have a silicone outer shell filled with sterile salt water. At the time of the 2000 decisions, the approvals covered breast augmentation for women aged 18 or older and breast reconstruction for women of any age. The devices could also be used in revision surgery within the approved indications. Those age and indication details matter because a regulatory approval answers a defined question about a defined device, population and use; it does not automatically apply to a different model, surface, manufacturing process or patient group.
Saline implants were not a risk-free alternative created by the approval date. A saline implant can deflate when the shell loses integrity, and the breast may then change size or shape. Other possible outcomes include reoperation, capsular contracture, pain, infection, asymmetry, scarring, changes in sensation and malposition. The practical appearance of a complication may differ from that of a silicone-gel rupture, but both are implanted medical devices that require informed consent and long-term attention.
The 2000 approvals therefore represented a regulatory conclusion about the evidence for those PMA applications and labelled uses. They did not mean that every future saline device would have identical performance, that every patient would have the same complication risk or that a patient would never need another operation.
The 2006 silicone approvals
The FDA records 17 November 2006 as the decision date for both major silicone gel-filled PMAs. Mentor’s P030053 application covered MemoryGel silicone gel-filled implants. Inamed’s P020056 application covered silicone-filled implants later identified by the FDA under the Natrelle name. The approval orders described breast augmentation for women at least 22 years old and reconstruction for women of any age, with revision surgery included within the stated augmentation or reconstruction indications.
The 2006 decision followed a long restricted-access period. In 1992, after concerns about the available evidence, the FDA restricted the routine use of silicone gel-filled implants in the United States while additional information was collected. During that period, silicone gel implants could still be used in controlled clinical studies and specified reconstructive or replacement circumstances. The 2006 approval therefore did not simply introduce silicone gel to American medicine for the first time. It marked the point at which the FDA considered the submitted evidence sufficient for a reasonable assurance of safety and effectiveness for the approved uses, subject to conditions that included further surveillance.
The FDA’s later summary described the two approved silicone products as having silicone shells filled with silicone gel and being available in different sizes and with smooth or textured shells. The details of a specific implant still matter. “Silicone implant” is not a complete device description: the model, gel characteristics, shell, surface, dimensions, indication and implantation date may all affect which information is relevant.
What FDA approval means—and what it does not mean
Breast implants are Class III medical devices. For this category, the FDA describes Premarket Approval, or PMA, as the most stringent device marketing pathway. The evidence must provide a reasonable assurance that the device is safe and effective for its intended use. The FDA weighs probable benefits against probable risks, considers the intended population and conditions of use, and reviews valid scientific evidence.
“Reasonable assurance” is a regulatory standard, not a promise of zero complications. It is also not the same as proving that a device will work identically for every person or remain intact indefinitely. A PMA approval is tied to the product and indications described in its approval order and labelling. It does not erase known risks, and it does not make later questions irrelevant.
The FDA’s Summary of Safety and Effectiveness Data, or SSED, explains the scientific evidence available at the time of a PMA decision. The original SSED is a snapshot of the premarket evidence. New information can later come from post-approval studies, adverse-event reports, device examinations, scientific publications, registries and clinical experience. When that information changes the balance of what patients need to know, patient and physician labelling can be updated.
This is why “FDA approved” should be read as “reviewed for reasonable assurance of safety and effectiveness for labelled use,” not “risk-free,” “permanent” or “suitable without individual assessment.” The same distinction applies to a CE mark or another regulatory status: a regulatory label is important information, but it does not replace clinical judgement, consent or follow-up.
Why post-approval studies were required after 2006
The 2006 silicone approvals included conditions requiring the manufacturers to continue studying long-term outcomes. The FDA’s post-approval framework recognises that premarket studies may be too small or too short to detect events that become more common with time or occur only rarely. Long-term surveillance can also test whether the outcomes observed in carefully selected trials resemble those in broader clinical practice.
For the Allergan Natrelle and Mentor MemoryGel approvals, the FDA described six broad post-approval study functions:
- Core studies: Prospective follow-up of patients enrolled in the clinical studies supporting the PMAs, designed to assess long-term clinical performance over approximately ten years.
- Large studies: Much larger cohorts intended to assess long-term outcomes and improve the ability to identify uncommon adverse events.
- Device-failure studies: Examination of explanted devices to understand how and why failures occurred.
- Focus-group studies: Testing patient information so that labelling could be made clearer and more useful.
- Informed-decision studies: Surveys assessing how physicians distributed and used patient information before implantation.
- Adjunct studies: Information about women who had received silicone gel-filled implants from 1992 to 2006, before broad approval, often for reconstruction or replacement of existing implants.
The design logic was complementary. A core cohort could provide detailed, long-term clinical information, but it might not be large enough to detect a very rare event. A large cohort could increase the number of observations, but a broad study might have less complete clinical detail. Device-failure analysis could clarify mechanical mechanisms, while focus groups could reveal whether patients understood the risks. No single study answered every question.
This programme also changed the meaning of approval. Approval became a point at which formal evidence collection continued, rather than the end of the evidence story. The FDA could require progress reports, review compliance with study conditions, request labelling changes and use postmarket information to communicate with patients and clinicians.
What the post-approval evidence added
A clearer picture of local complications and later surgery
The FDA’s 2011 update reported that the local complications seen in silicone gel-filled implant post-approval studies were generally consistent with complications already recognised at approval. Common outcomes included capsular contracture, reoperation and implant removal; other reported outcomes included rupture, wrinkling, asymmetry, scarring, pain and infection.
The update also showed why duration matters. In the core studies, between 20% and 40% of augmentation patients and 40% to 70% of reconstruction patients had undergone reoperation during the first eight to ten years, depending on the cohort and time point. The FDA reported that as many as one in five primary augmentation patients and one in two primary reconstruction patients required device removal within ten years in the available study data. These figures are not a personal forecast and should not be transferred directly to every current implant. They illustrate a broader conclusion: the longer an implant remains in place, the more opportunity there is for a local complication, a change in the surrounding breast or a change in the patient’s goals to lead to further surgery.
The difference between augmentation and reconstruction is particularly important. Reconstruction patients may have had mastectomy, radiotherapy, altered tissue coverage or other medical factors that do not apply to a primary cosmetic augmentation. Combining those groups into one headline rate can mislead readers.
Better understanding of silent rupture and device failure
Silicone gel rupture may be silent, meaning that the patient does not notice an obvious change. The post-approval programme helped maintain attention on imaging and on the difference between a clinical symptom and an imaging finding. Device-failure studies added another perspective by examining returned or explanted implants and asking what physical mechanisms were associated with failure.
Current FDA information recommends that patients with silicone gel-filled implants follow device-specific rupture-screening advice. For asymptomatic patients, the FDA describes ultrasound or MRI as screening options beginning five to six years after implantation and repeating every two to three years. Symptoms, an abnormal examination or an uncertain ultrasound result may require a different diagnostic pathway. This monitoring guidance is separate from routine breast-cancer screening.
The practical lesson is that a patient should retain the manufacturer, model and device record. Later clinicians cannot interpret an implant history accurately if the filler, surface and implantation date are unknown. A device card is a communication tool, not a guarantee against rupture.
A more realistic view of evidence gaps
The post-approval studies did not turn every unknown into a known fact. The FDA’s 2011 review stated that the available data did not show evidence that silicone gel-filled implants caused connective-tissue disease, reproductive problems or breast cancer. At the same time, the FDA cautioned that low follow-up rates and other limitations could restrict interpretation and make very rare complications difficult to detect.
That combination is scientifically important. “No evidence of a causal association in the available studies” is not the same as “every possible long-term risk has been excluded.” Conversely, a report of a symptom after implantation does not by itself establish that the implant caused it. A sound interpretation keeps both errors in check: it neither converts uncertainty into alarm nor treats an incomplete study as proof of permanent safety.
Why follow-up limitations matter
Loss to follow-up can change the apparent rate
Long-term studies depend on people returning, answering questions and completing examinations. In the FDA’s 2011 summary, the Allergan core study had 66% follow-up at ten years, while the Mentor core study had 58% follow-up at eight years. The large studies enrolled more than 40,000 silicone patients for each manufacturer, but early follow-up completion was also below the intended target at the time of that update.
When a substantial proportion of participants is not observed, researchers cannot assume that those missing patients had the same outcomes as those who remained. Some may have been well and moved on; others may have had a reoperation elsewhere, changed address, lost contact with the study or stopped participating after a complication. The direction and size of the resulting bias are not always knowable.
Study populations do not represent every patient
Core studies are not random samples of every woman who might receive an implant. They use eligibility criteria and may be conducted in selected centres. Large studies can be more representative, but they still depend on enrolment, record quality and outcome definitions. Augmentation, reconstruction and revision patients have different baseline risks, and a result from one group should not be presented as though it describes all three.
Rare events require appropriate designs
Even a very large cohort may not be able to estimate an extremely rare outcome precisely, particularly if follow-up is incomplete or the event definition changes. A study designed for common local complications may be poorly suited to detecting a disease that appears years later. This is one reason the FDA uses multiple surveillance tools, including adverse-event reports, scientific literature, registries and device-specific post-approval studies.
Devices change over time
A 2006 implant is not automatically identical to a current implant. Shell construction, gel formulation, surface, manufacturing controls, labelling and indications may change through approved supplements or new PMAs. Findings from an older cohort are valuable historical evidence, but they must be matched to the device being discussed. A broad search for “silicone implant safety” cannot replace reviewing the current patient labelling for a specific model.
The FDA’s current postmarket pages show that some breast-implant studies are completed, some have been redesigned or replaced and others remain ongoing. This is not evidence that the original approvals were meaningless. It is evidence that long-term medical-device surveillance is an evolving process, and that the status of a study matters when interpreting a claim.
Why approval is not a lifetime guarantee
The FDA explicitly states that breast implants are not lifetime devices. The statement does not create a mandatory replacement date. It means that the probability of complications or additional surgery can increase over time, and that a patient should plan for the possibility of monitoring, removal, replacement or revision.
There are several reasons an approved implant may not remain the final operation:
- The shell may rupture or, in the case of a saline device, deflate.
- Capsular contracture may make the breast firm, painful or distorted.
- The implant may move, become visible or palpable, or contribute to asymmetry.
- Pregnancy, breastfeeding, weight change and ageing may alter the breast around an intact implant.
- A patient’s preferences may change, leading to a discussion of replacement or removal.
- New information may change the monitoring or counselling appropriate for a device or surface.
An implant can therefore be approved, intact and functioning as intended while the breast still changes with time. Conversely, a patient may have an intact implant and no clinical reason for automatic replacement simply because ten years have passed. Decisions should be based on symptoms, examination, imaging where appropriate, device-specific information and the patient’s goals.
What this history means for a patient today
The main lesson from the 2000 saline and 2006 silicone approvals is not that one filler is universally better. It is that a responsible decision uses several layers of information:
- Identify the exact implant: manufacturer, model, filler, surface, dimensions and implantation date.
- Read the current patient labelling and decision materials, not only an old approval headline.
- Ask what complications are most relevant to the proposed device and to the patient’s own tissue coverage and history.
- Understand how suspected rupture, late swelling, pain, firmness or shape change would be assessed.
- Keep the implant record and operative note for future imaging and clinical care.
- Discuss the possibility of additional surgery without assuming either automatic replacement or permanent device performance.
For procedural context, the local breast augmentation operation information explains anatomy-based planning and the clinical pathway. It should be read alongside official device labelling rather than used as a substitute for it. The practical silicone versus saline breast implant guide explains filler differences in plainer language, while the breast implant longevity guide discusses why there is no universal expiry date. Readers focused on silent rupture can also review the silent breast implant rupture guide.
The 2006 silicone breast implant approval answered a regulatory question: did the evidence provide reasonable assurance of safety and effectiveness for the labelled device and uses? Post-approval studies answered additional questions about long-term complications, reoperation, device failure, communication and the limits of available data. Together, the approvals and the later evidence support a balanced conclusion: breast implants can be appropriate for selected patients, but approval is conditional, evidence continues after marketing begins and no approval can promise a lifetime without complications or further surgery.
Evidence limitations
This article focuses on FDA decisions in the United States and uses the approval records and FDA summaries available on 10 September 2026. The 2000 milestone refers to the 10 May 2000 PMA decisions for Mentor P990075 and McGhan P990074; later supplements and changes to ownership or product names should not be confused with a new original approval. The 2006 milestone refers to the 17 November 2006 decisions for Mentor P030053 and Inamed P020056.
The post-approval evidence includes different designs, cohorts, indications and follow-up periods. The FDA’s 2011 summary is historically important but does not represent every later study update or every currently marketed implant. Reported reoperation and removal findings came from particular cohorts and cannot be used as a personal risk calculation. Reconstruction, revision and primary cosmetic augmentation are not interchangeable populations.
Long-term interpretation is limited by incomplete follow-up, participant selection, changes in device design, inconsistent outcome definitions and the difficulty of detecting very rare events. A completed study is not automatically a perfect study, and an ongoing or redesigned study is not automatically evidence of harm. Current patients should review the latest device-specific labelling and discuss symptoms, imaging and long-term decisions with a qualified healthcare professional.